You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

AIM4CML,

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

PROSPECT - Profiling of Resistance Patterns & Oncogenic

Recruiting
  • Lung Cancer
  • Cancer of Thorax
  • Group Specific Aim 1
  • +5 more
  • Houston, Texas
    M D Anderson Caner Center
Jun 29, 2022

Clinical Pathways for Newly Diagnosed Multiple Myeloma

Not yet recruiting
  • Multiple Myeloma
  • Multiple Myeloma Without Mention of Remission
  • Multiple Myeloma Pathway
  • +2 more
  • (no location specified)
Nov 27, 2023

Diagnostic and Evaluation Tool for Lower Limb Lymphedema: Aim 4

Not yet recruiting
  • Lower Limb Lymphedema
  • 2 clinical evaluations with 1 month in between
  • Leuven, Belgium
  • +1 more
Sep 8, 2023

Composition & Function of Sarcoplasmic Reticulum in Persons With

Active, not recruiting
  • Metabolic Syndrome
  • muscle biopsy
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 20, 2022

Obesity, Pediatric Trial in Canada (Aim2Be app with Live Coach + Fitbit + BMI tracking tools, Aim2Be app waitlist + Canadian

Completed
  • Obesity, Pediatric
  • Aim2Be app with Live Coach + Fitbit + BMI tracking tools
  • Aim2Be app waitlist + Canadian Health Recommendations + Fitbit + BMI tracking tools, then flip to Aim2Be app with Virtual Coach + Fitbit + BMI tracking tools
  • Calgary, Alberta, Canada
  • +5 more
Jun 23, 2022

Withdrawal or Reduction TKIs in CML-CP

Recruiting
  • MMR on 12 Month
  • withdrawal TKIs or halve TKIs
  • Guangzhou, Guangdong, China
    NanfangH
Sep 2, 2021

CML, Chronic Phase Trial in Harbin (Flumatinib mesylate tablets (400mg), Flumatinib mesylate tablets (600mg))

Recruiting
  • CML, Chronic Phase
  • Flumatinib mesylate tablets (400mg)
  • Flumatinib mesylate tablets (600mg)
  • Harbin, Hei Longjiang, China
    Institute of Hematology and Oncology, Harbin The First Hospital
Apr 28, 2022

Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory Trial in Worldwide (Radotinib HCl)

Recruiting
  • Chronic Myeloid Leukemia, Chronic Phase
  • +3 more
  • Radotinib HCl
  • Uijeongbu-si, Gyeonggi-do, Korea, Republic of
  • +17 more
Jan 3, 2022

Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Trial in

Recruiting
  • Acute Biphenotypic Leukemia
  • +13 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 19, 2023

Chronic Migraine, Headache Trial (PainCOACH Pain Coping Skills Training, Treatment as Usual)

Withdrawn
  • Chronic Migraine, Headache
  • PainCOACH Pain Coping Skills Training
  • Treatment as Usual
  • (no location specified)
Mar 12, 2021

CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic Trial in Worldwide (Asciminib add-on, Imatinib, Nilotinib)

Recruiting
  • CML
  • +3 more
  • Asciminib add-on
  • +3 more
  • Augusta, Georgia
  • +46 more
Jan 23, 2023

Alzheimer's Disease and Related Dementias Trial in Glen Oaks, Manhasset (PES-4-BPSD Model, The attention control condition)

Completed
  • Alzheimer's Disease and Related Dementias
  • PES-4-BPSD Model
  • The attention control condition
  • Glen Oaks, New York
  • +1 more
Jan 6, 2022

Smoking, Binge Eating, Behavior Trial in Stanford (Laddr)

Recruiting
  • Smoking
  • +2 more
  • Laddr
  • Stanford, California
    Stanford Center for Cognitive and Neurobiological Imaging
Sep 20, 2021

Self-regulation, Binge Eating, Smoking Trial in Lebanon (Laddr)

Completed
Has Results
  • Self-regulation
  • +2 more
  • Laddr
  • Lebanon, New Hampshire
    Center for Technology and Behavioral Health, Dartmouth College
Jul 29, 2021

Triple -Negative Breast Cancer, Estrogen Receptor Negative, HER2/Neu Negative Trial in Buffalo (procedure, drug, biological)

Active, not recruiting
  • Triple -Negative Breast Cancer
  • +4 more
  • Biopsy
  • +5 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Aug 1, 2022

Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow

Recruiting
  • Acute Myeloid Leukemia
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 31, 2022

Migraine, Episodic Migraine, Phonophobia Trial in United States (Rimegepant)

Recruiting
  • Migraine
  • +3 more
  • Phoenix, Arizona
  • +18 more
Jun 3, 2022

Malaria, Febrile Illness Trial in Eldoret (Conditional ACT subsidy, Arm 1 levels, Conditional ACT subsidy, Arm 2 levels,

Completed
Has Results
  • Malaria
  • Febrile Illness
  • Conditional ACT subsidy, Arm 1 levels
  • +3 more
  • Eldoret, Kenya
    Moi University
Oct 20, 2020

Chronic Myelogenous Leukemia Trial in Worldwide (ABL001 40mg BID, ABL001 80mg QD, ABL001 200mg QD)

Recruiting
  • Chronic Myelogenous Leukemia
  • ABL001 40mg BID
  • +2 more
  • Caba, Buenos Aires, Argentina
  • +53 more
Jan 27, 2023

Expression Pattern of HNRNPH1 and HNRNPK Genes in MPNs

Not yet recruiting
  • Myeloproliferative Neoplasms (MPNs)
  • Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
  • (no location specified)
Mar 24, 2023

GIST and CML Trial in Worldwide (AMN107)

Active, not recruiting
  • GIST and CML
  • Albany, New York
  • +32 more
Oct 4, 2022

Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Worldwide (Nilotinib)

Completed
Has Results
  • Chronic Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Bordeaux, Aquitaine, France
  • +11 more
Dec 6, 2020

CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey

Completed
  • Chronic Phase Chronic Myelogenous Leukemia
  • +3 more
    • Limerick, Dooradoyle, Ireland
    • +32 more
    Aug 13, 2021

    Chronic Myelogenous Leukemia Trial in Worldwide (Asciminib, Bosutinib)

    Active, not recruiting
    Has Results
    • Chronic Myelogenous Leukemia
    • Chicago, Illinois
    • +87 more
    Jan 20, 2023

    Myeloid Leukemia, Philadelphia Positive Trial in Worldwide (Asciminib Pediatric formulation group, Asciminib Adult formulation

    Recruiting
    • Myeloid Leukemia, Philadelphia Positive
    • Asciminib Pediatric formulation group
    • Asciminib Adult formulation group
    • Boston, Massachusetts
    • +24 more
    Jan 17, 2023